Accueil › Annuaire des chercheurs › George M. Warimwe
George M. Warimwe
Affiliation : Kenya Medical Research Institute · KEMRI-Wellcome Trust Research Programme
- 62Publications (affiliation kényane)
Profil de recherche
George M. Warimwe compte 62 publications référencées (2007–2026). Ses travaux paraissent principalement dans « Wellcome Open Research », « The Lancet Infectious Diseases » et « Vaccines ». Son article le plus cité, « Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors » (2020), a été cité 328 fois. 5 de ces publications datent des trois dernières années d’activité. Ses travaux sont cosignés avec au moins 12 chercheurs, notamment dans des établissements de Royaume-Uni, États-Unis, Suède, Afrique du Sud.
C’est vous ? Faites connaître vos travaux
Créez gratuitement votre profil DzCademia et ajoutez vos articles : ils apparaîtront plus facilement sur Google et dans les assistants d’IA comme ChatGPT. Plus de personnes pourront vous lire et vous citer.
Créer mon profil gratuit Ajouter mes publicationsPublications (62)
- Low-dose yellow fever vaccination in infants: a randomised, double-blind, non-inferiority trial
- Low-Dose Yellow Fever Vaccine in Adults in Africa
- Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial
- Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya
- Severe morbidity and hospital-based mortality from Rift Valley fever disease between November 2017 and March 2020 among humans in Uganda
- Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
- SARS‐CoV‐2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February–December 2022
- Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial
- Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial
- A Customizable Suite of Methods to Sequence and Annotate Cattle Antibodies
- Symptom prevalence and secondary attack rate of SARS‐CoV‐2 in rural Kenyan households: A prospective cohort study
- Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial
- Clinical manifestations of Rift Valley fever in humans: Systematic review and meta-analysis
- Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya
- SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021
- Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020–21
- Transmission networks of SARS-CoV-2 in Coastal Kenya during the first two waves: A retrospective genomic study
- Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data
- Incidence of chikungunya virus infections among Kenyan children with neurological disease, 2014–2018: A cohort study
- The global burden of Chikungunya fever among children: A systematic literature review and meta-analysis
- Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya
- Serum immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro
- Assessing the Level and Determinants of COVID-19 Vaccine Confidence in Kenya
- COVID-19 transmission dynamics underlying epidemic waves in Kenya
- Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya
- Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial
- Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021
- Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya
- Tracking the introduction and spread of SARS-CoV-2 in coastal Kenya
- Using cross-species vaccination approaches to counter emerging infectious diseases
- Endemic chikungunya fever in Kenyan children: a prospective cohort study
- Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya
- Quantifying previous SARS-CoV-2 infection through mixture modelling of antibody levels
- Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations
- Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
- Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data
- What Constitutes Protective Immunity Following Yellow Fever Vaccination?
- Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors
- Naturally Acquired Rift Valley Fever Virus Neutralizing Antibodies Predominantly Target the Gn Glycoprotein
- Urban Ecology of Arboviral Mosquito Vectors Along the Kenyan Coast
- Rift Valley fever: biology and epidemiology
- Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats
- Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components
- Congenital microcephaly unrelated to flavivirus exposure in coastal Kenya
- Complete Genome Sequences of Dengue Virus Type 2 Strains from Kilifi, Kenya
- Exploring Plasmodium falciparum Var Gene Expression to Assess Host Selection Pressure on Parasites During Infancy
- Systematic literature review of Rift Valley fever virus seroprevalence in livestock, wildlife and humans in Africa from 1968 to 2016
- A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus
- Association between Rift Valley fever virus seroprevalences in livestock and humans and their respective intra-cluster correlation coefficients, Tana River County, Kenya
- Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model
- Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology
- Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever
- Global selection of Plasmodium falciparum virulence antigen expression by host antibodies
- Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle
- Plasmodium falciparumantigenic variation: relationships between widespread endothelial activation, parasite PfEMP1 expression and severe malaria
- Plasmodium falciparum var Gene Expression Homogeneity as a Marker of the Host-Parasite Relationship under Different Levels of Naturally Acquired Immunity to Malaria
- Targets of antibodies against Plasmodium falciparum–infected erythrocytes in malaria immunity
- Prognostic Indicators of Life-Threatening Malaria Are Associated with Distinct Parasite Variant Antigen Profiles
- Plasmodium falciparum var gene expression is modified by host immunity
- Analysis of Immunity to Febrile Malaria in Children That Distinguishes Immunity from Lack of Exposure
- Haemoglobin C and S Role in Acquired Immunity against Plasmodium falciparum Malaria
- In Vitro Inhibition of Plasmodium falciparum Rosette Formation by Curdlan Sulfate
Revues de publication
- Wellcome Open Research × 5
- The Lancet Infectious Diseases × 4
- Vaccines × 4
- BMC Infectious Diseases × 3
- PLoS ONE × 3
- Nature Communications × 3
Publications par année
- 20261
- 20252
- 20242
- 20237
- 202210
- 202115
- 20203
- 20196
- 20183
- 20172
Collaborations
Établissements partenaires : Ministry of Health · University of Oxford · Government of Kenya · London School of Hygiene & Tropical Medicine · Kenya National Blood Transfusion Services
Pays des co-auteurs : Royaume-Uni · États-Unis · Suède · Afrique du Sud
Co-auteurs
- Philip Bejon
- John N. Gitonga
- Henry Karanja
- Lynette Isabella Ochola‐Oyier
- Charles N. Agoti
- Ambrose Agweyu
- Daisy Mugo
- James Nyagwange
- Edwine Barasa
- Kadondi Kasera
- J. Anthony G. Scott
- Benjamin Tsofa
Données bibliographiques issues d’OpenAlex (base ouverte).
Pourquoi choisir Dzcademia ?
Pour donner à vos travaux plus de chances d’être découverts et recommandés par les IA. Profils, articles et communications : donnez à votre recherche une présence publique structurée. Les métadonnées intégrées aident les moteurs de recherche et les assistants IA à identifier vos travaux et à comprendre leurs références.
Commenter avec Google
Connecte-toi avec Google pour commenter directement sur cette page.